| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2019-02-15 |
复牌提示：
2019-02-15 09:02:58 停牌，复牌日期 2019-02-19 00:00:01
|
| 2019-02-15 |
详情>>
内部人交易：
Bilenker Joshua H.等共交易6笔
|
| 2018-11-08 |
详情>>
股本变动：
变动后总股本3061.45万股
|
| 2018-11-08 |
财报披露：
美东时间 2018-11-08 盘前发布财报
|
| 2018-11-08 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-1.4美元,归母净利润-4234.8万美元,同比去年增长66.98%
|
| 2018-08-09 |
财报披露：
美东时间 2018-08-09 盘前发布财报
|
| 2018-08-09 |
详情>>
业绩披露：
2018年中报每股收益-0.51美元,归母净利润-1528.4万美元,同比去年增长72.17%
|
| 2018-05-08 |
财报披露：
美东时间 2018-05-08 盘前发布财报
|
| 2018-05-08 |
详情>>
业绩披露：
2018年一季报每股收益-0.12美元,归母净利润-355.8万美元,同比去年增长85.49%
|
| 2018-04-30 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors of Loxo Oncology, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
3.To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.
4.To conduct a non-binding advisory vote on the frequency of holding future advisory votes on named executive officer compensation
5.To amend and restate Loxo Oncology, Inc.’s 2014 Equity Incentive Plan to increase the number of shares reserved thereunder by an additional 1,500,000 shares, and to approve amendments to the 2014 Plan to (i) to increase the “evergreen” from 3% to 4% but to reduce the term of such “evergreen” to calendar years through January 1, 2023, (ii) impose a limit of 30,000 shares as the maximum number of shares that may be granted under the 2014 Plan to each of our non-employee directors each year, (iii) prohibit shares that are withheld from exercised shares for taxes, payment of exercise price in connection with the exercise of options or stock appreciation rights from returning to the total number of shares reserved for awards, (iv) provide for a prohibition on payment of dividends on unvested awards, (v) prohibit repricing without stockholder approval, (vi) prohibit transfer of awards to third-party institutions for value and (vii) make certain modifications to reflect changes to the tax law by 2017 tax legislation.
|
| 2018-03-01 |
财报披露：
美东时间 2018-03-01 盘前发布财报
|
| 2018-03-01 |
详情>>
业绩披露：
2017年年报每股收益-5.31美元,归母净利润-1.49亿美元,同比去年增长-105.64%
|
| 2018-03-01 |
详情>>
业绩披露：
2015年年报每股收益-2.12美元,归母净利润-3587.6万美元,同比去年增长-73.26%
|
| 2017-11-02 |
财报披露：
美东时间 2017-11-02 盘前发布财报
|
| 2017-11-02 |
详情>>
业绩披露：
2017年三季报(累计)每股收益-4.68美元,归母净利润-1.28亿美元,同比去年增长-183.71%
|
| 2017-08-08 |
财报披露：
美东时间 2017-08-08 盘前发布财报
|
| 2017-08-08 |
详情>>
业绩披露：
2016年中报每股收益-1.36美元,归母净利润-2751.3万美元,同比去年增长-93.24%
|
| 2017-08-08 |
详情>>
业绩披露：
2017年中报每股收益-2.1美元,归母净利润-5492.9万美元,同比去年增长-99.65%
|
| 2017-05-09 |
详情>>
业绩披露：
2017年一季报每股收益-0.96美元,归母净利润-2452.8万美元,同比去年增长-111.5%
|
| 2017-05-01 |
股东大会：
将于2017-06-22召开股东大会
会议内容 ▼▲
- 1. To elect three Class III directors of Loxo Oncology, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2. To ratify the appointment of Ernst Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
|
| 2017-03-07 |
详情>>
业绩披露：
2016年年报每股收益-3.46美元,归母净利润-7239.8万美元,同比去年增长-101.8%
|
| 2016-11-02 |
详情>>
业绩披露：
2016年三季报(累计)每股收益-2.19美元,归母净利润-4520.4万美元,同比去年增长-96.46%
|
| 2016-04-18 |
股东大会：
将于2016-06-10召开股东大会
会议内容 ▼▲
- 1. To elect three Class II directors of Loxo Oncology, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2. To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
|
| 2015-04-23 |
股东大会：
将于2015-06-10召开股东大会
会议内容 ▼▲
- 1. To elect two Class I directors of Loxo Oncology, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2. To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
3. To re-approve the Internal Revenue Code Section 162(m) limits of our 2014 Equity Incentive Plan to preserve our ability to receive corporate income tax deductions that may become available pursuant to Section 162(m).
|